Marinus Pharmaceuticals (NASDAQ:MRNS) issued its quarterly earnings data on Tuesday, March 6th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.07), Yahoo Finance reports.
Marinus Pharmaceuticals (NASDAQ:MRNS) traded down $0.11 during trading on Wednesday, hitting $4.28. The stock had a trading volume of 703,569 shares, compared to its average volume of 1,200,000. Marinus Pharmaceuticals has a twelve month low of $1.13 and a twelve month high of $9.87. The stock has a market capitalization of $173.04, a PE ratio of -5.22 and a beta of 2.42.
MRNS has been the subject of a number of research reports. BidaskClub upgraded Marinus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, December 30th. Laidlaw assumed coverage on Marinus Pharmaceuticals in a research note on Thursday, December 14th. They issued a “buy” rating and a $18.00 price objective for the company. HC Wainwright assumed coverage on Marinus Pharmaceuticals in a research note on Thursday, February 15th. They set a “buy” rating and a $33.00 price target for the company. Finally, ValuEngine cut Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. Marinus Pharmaceuticals presently has an average rating of “Hold” and an average price target of $20.67.
In related news, CEO Christopher Michael Cashman sold 9,566 shares of the company’s stock in a transaction on Thursday, January 18th. The stock was sold at an average price of $6.28, for a total transaction of $60,074.48. Following the transaction, the chief executive officer now owns 247,903 shares of the company’s stock, valued at $1,556,830.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Bain Capital Life Sciences Inv sold 1,272,547 shares of the company’s stock in a transaction on Tuesday, December 19th. The stock was sold at an average price of $7.88, for a total value of $10,027,670.36. The disclosure for this sale can be found here. Insiders have sold 2,107,660 shares of company stock valued at $16,774,106 in the last 90 days. Company insiders own 4.60% of the company’s stock.
WARNING: “Marinus Pharmaceuticals (MRNS) Announces Earnings Results, Misses Estimates By $0.07 EPS” was first reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at https://www.thelincolnianonline.com/2018/03/14/marinus-pharmaceuticals-mrns-releases-earnings-results-misses-expectations-by-0-07-eps.html.
About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.